Drug:
Reaction: ECZEMA
20250101 - 20251231
No. 101 - 200
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 101 | 25846229 |
US |
25 | 1 |
Eczema, Rebound effect, Product dose omission in error, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 102 | 25846271 |
US |
1 | |
Eczema, Rebound effect, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 103 | 25846273 |
US |
13 | 2 |
Eczema, Intentional dose omission, |
||||
DUPILUMAB, |
||||
| 104 | 25846334 |
US |
59 | 1 |
Ocular hyperaemia, Eczema, Erythema, Dry skin, Pruritus, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 105 | 25846488 |
US |
12 | 1 |
Eczema, |
||||
DUPILUMAB, MUPIROCIN, MUPIROCIN CALCIUM, |
||||
| 106 | 25846654 |
US |
2 | |
Eczema, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 107 | 25846655 |
CA |
||
Aphonia, Blood pressure increased, Bronchitis, Cardiomegaly, Cellulitis, Dysphonia, Dyspnoea exertional, Eczema, Erythema, Fall, Hypoaesthesia, Insomnia, Joint dislocation, Multiple fractures, Oropharyngeal pain, Pain, Pain in extremity, Phlebitis, Plasma cell myeloma, Pneumonia, Productive cough, Respiratory syncytial virus infection, Respiratory tract congestion, Secretion discharge, Shoulder fracture, Sputum discoloured, Thrombophlebitis, Thrombosis, Urinary tract infection, Abdominal pain upper, Angina unstable, Arthralgia, Cough, Diarrhoea, Drug hypersensitivity, Fatigue, Illness, Myalgia, Pruritus, Pyrexia, Urticaria, Wrong technique in product usage process, |
||||
OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, CLINDAMYCIN PHOSPHATE, CLINDAMYCIN, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE, MONTELUKAST, MONTELUKAST SODIUM, TIOTROPIUM BROMIDE, ALBUTEROL SULFATE, |
||||
| 108 | 25846745 |
US |
15 | 2 |
Eczema, Rebound effect, Skin discomfort, |
||||
DUPILUMAB, |
||||
| 109 | 25846758 |
US |
2 | |
Weight increased, Nausea, Somnolence, Eczema, Off label use, |
||||
APREMILAST, APREMILAST, DUPILUMAB, |
||||
| 110 | 25847130 |
US |
72 | 2 |
Eczema, Rebound effect, Erythema, Pruritus, Skin exfoliation, Incorrect dose administered, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 111 | 25847818 |
51 | 2 | |
Eczema, Skin discolouration, |
||||
LEBRIKIZUMAB-LBKZ, |
||||
| 112 | 25847834 |
US |
47 | 2 |
Eczema, Inappropriate schedule of product administration, Rebound effect, |
||||
DUPILUMAB, DESONIDE, DAPSONE GEL, 5%, DAPSONE, DASPONE, |
||||
| 113 | 25848497 |
US |
31 | 2 |
Eczema, Rebound effect, |
||||
DUPILUMAB, |
||||
| 114 | 25848627 |
US |
77 | 1 |
Eczema, |
||||
DUPILUMAB, DUPILUMAB, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, |
||||
| 115 | 25848640 |
US |
38 | 2 |
Myalgia, Hypoaesthesia, Musculoskeletal chest pain, Dyspnoea, Sleep disorder due to a general medical condition, Headache, Dizziness, Vomiting, Gait disturbance, Confusional state, Memory impairment, Eczema, Gingivitis, Toothache, Arthralgia, |
||||
DUPILUMAB, CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE, TIRZEPATIDE, |
||||
| 116 | 25849074 |
CN |
61 | 1 |
Paradoxical skin reaction, Pulmonary tuberculosis, Eczema, |
||||
IXEKIZUMAB, IXEKIZUMAB, IXEKIZUMAB, |
||||
| 117 | 25849137 |
US |
66 | 2 |
Eczema, |
||||
DUPILUMAB, DUPILUMAB, MEPOLIZUMAB, |
||||
| 118 | 25839254 |
CA |
||
Intestinal obstruction, Colorectal cancer, Poor venous access, Contusion, Diverticulum intestinal, Pruritus, Eczema, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, HYDROCORTISONE, |
||||
| 119 | 25840353 |
JP |
||
Neutropenia, Lymphopenia, Anaemia, Leukopenia, Thrombocytopenia, Gastroenteritis, Cytokine release syndrome, Dermatitis bullous, Pneumonia, Plasma cell myeloma, Hypogammaglobulinaemia, Hypercalcaemia of malignancy, Adverse event, Hypoxia, Upper respiratory tract infection, COVID-19, Conjunctival haemorrhage, Weight decreased, Pyrexia, Injection site erythema, Malaise, Injection site warmth, Hypogeusia, Dysgeusia, Dyskinesia, Taste disorder, Diarrhoea, Nausea, Dysphagia, Vomiting, Abdominal pain, Aphthous ulcer, Constipation, Dry mouth, Gastrooesophageal reflux disease, Irritable bowel syndrome, Stomatitis, Alopecia, Skin exfoliation, Eczema, Nail disorder, Dry skin, Eczema nummular, Erythema, Hand dermatitis, Nail discolouration, Onychomadesis, Pruritus, Rash, Rash maculo-papular, Dermatophytosis of nail, Herpes zoster, Nasopharyngitis, Otitis media, Tinea pedis, Hyperglycaemia, Hypozincaemia, Decreased appetite, Hyperammonaemia, Arthralgia, Joint range of motion decreased, Muscular weakness, Myalgia, Neck pain, Spinal deformity, Tinnitus, Vertigo, Alanine aminotransferase increased, Aspartate aminotransferase increased, Lipase increased, Cancer pain, Skin papilloma, Tumour associated fever, Hiccups, Oropharyngeal pain, Rhinorrhoea, Diplopia, Dry eye, Nail avulsion, Mental disorder, Insomnia, Anxiety, Bundle branch block right, Prostatic obstruction, |
||||
CARFILZOMIB, FILGRASTIM, TALQUETAMAB, BORTEZOMIB FOR INJECTION, BORTEZOMIB, IXAZOMIB, THALIDOMIDE, LENALIDOMIDE, POMALIDOMIDE, ISATUXIMAB, ACYCLOVIR, LEVOFLOXACIN, LEVOFLOXACIN IN 5% DEXTROSE, CYANOCOBALAMIN, PYRIDOXINE HYDROCHLORIDE, ZINC ACETATE, |
||||
| 120 | 25840834 |
US |
66 | 2 |
Migraine, Nystagmus, Diplopia, Vertigo, Dry eye, Stress, Eczema, Skin burning sensation, |
||||
DUPILUMAB, |
||||
| 121 | 25841672 |
EU |
16 | 2 |
Topical steroid withdrawal reaction, Mood swings, Eczema, |
||||
HYDROCORTISONE BUTYRATE, MOMETASONE FUROATE, MOMETASONE, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, |
||||
| 122 | 25841779 |
EU |
29 | 2 |
Rheumatoid arthritis, Arthralgia, Lymphadenopathy, Bone pain, Back pain, Musculoskeletal stiffness, Malaise, Fatigue, Hypotonia, Malaise, Eczema, |
||||
| 123 | 25842509 |
US |
1 | |
Immunosuppression, Eczema nummular, Wheezing, Rales, Rash, Eczema, Skin lesion, Seborrhoeic keratosis, Swelling, Dry skin, Pruritus, Pain, Urticaria, Skin mass, Asthma, Cough, Seasonal allergy, Dermatitis contact, |
||||
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, CLINDAMYCIN PHOSPHATE, CLINDAMYCIN, DESONIDE, KETOCONAZOLE, KETOCONAZOLE FOAM, KETOCONAZOLE CREAM, 2%, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, ZAFIRLUKAST, EPINEPHRINE, FLUTICASONE PROPIONATE, CLARITHROMYCIN, LEVOFLOXACIN, LEVOFLOXACIN IN 5% DEXTROSE, PREDNISONE, |
||||
| 124 | 25843044 |
US |
24 | 2 |
Eczema, |
||||
DUPILUMAB, |
||||
| 125 | 25843099 |
US |
46 | 1 |
Eye disorder, Eczema, Eye discharge, Eye pruritus, |
||||
DUPILUMAB, ROSUVASTATIN CALCIUM, MONTELUKAST SODIUM, MONTELUKAST, MOMETASONE FUROATE, MOMETASONE, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, AZELASTINE HYDROCHLORIDE, AZELASTINE, AZELASTINE HYDROCHLORIDE, AZELASTINE, ALBUTEROL SULFATE, BUDESONIDE AND FORMOTEROL FUMARATE, |
||||
| 126 | 25843102 |
US |
2 | |
Eczema, |
||||
DUPILUMAB, ONDANSETRON HYDROCHLORIDE, TIRZEPATIDE, GABAPENTIN, PANTOPRAZOLE SODIUM, |
||||
| 127 | 25843126 |
US |
21 | 2 |
Eczema, Pruritus, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 128 | 25843200 |
US |
1 | |
Eczema, Drug ineffective, |
||||
DUPILUMAB, |
||||
| 129 | 25843228 |
US |
44 | 2 |
Eczema, |
||||
DUPILUMAB, |
||||
| 130 | 25843236 |
US |
55 | 2 |
Eczema, Pruritus, Skin fissures, Skin haemorrhage, Dry skin, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 131 | 25843239 |
US |
9 | 1 |
Eczema, Rash, Rebound effect, Product dose omission issue, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 132 | 25843251 |
US |
18 | 2 |
Eczema, |
||||
DUPILUMAB, FISH OIL, ERGOCALCIFEROL, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, |
||||
| 133 | 25843280 |
US |
28 | 2 |
Eczema, Pruritus, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 134 | 25843295 |
US |
1 | |
Eczema, |
||||
DUPILUMAB, |
||||
| 135 | 25843298 |
US |
11 | 2 |
Eczema, Rebound effect, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 136 | 25843336 |
US |
12 | 2 |
Eczema, Off label use, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 137 | 25843357 |
US |
24 | 1 |
Eczema, Pruritus, Dry skin, Skin exfoliation, |
||||
DUPILUMAB, |
||||
| 138 | 25843366 |
US |
23 | 2 |
Eczema, |
||||
DUPILUMAB, |
||||
| 139 | 25843382 |
US |
80 | 2 |
Psychomotor hyperactivity, Oxygen consumption increased, Skin exfoliation, Dermatitis atopic, Eczema, Pruritus, Scratch, Sleep disorder due to a general medical condition, |
||||
DUPILUMAB, |
||||
| 140 | 25843387 |
US |
26 | 1 |
Eczema, |
||||
DUPILUMAB, |
||||
| 141 | 25843446 |
US |
4 | 2 |
Eczema, Drug ineffective, |
||||
DUPILUMAB, |
||||
| 142 | 25843500 |
US |
3 | 1 |
Middle insomnia, Eczema, Dermatitis, Pruritus, |
||||
DUPILUMAB, |
||||
| 143 | 25843707 |
US |
18 | 2 |
Eczema, Rebound effect, Product dose omission issue, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 144 | 25833758 |
US |
56 | 1 |
Eczema, Nasopharyngitis, Headache, |
||||
RISANKIZUMAB-RZAA, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, METOPROLOL TARTRATE, METOPROLOL, PANTOPRAZOLE, LEVOTHYROXINE, |
||||
| 145 | 25833819 |
US |
27 | 2 |
Eczema, Rebound effect, Rash, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 146 | 25833944 |
US |
7 | 1 |
Eczema, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 147 | 25833954 |
US |
57 | 2 |
Eczema, Skin haemorrhage, Rebound effect, Product dose omission issue, Hypersensitivity, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 148 | 25834089 |
EU |
23 | 2 |
Eczema, Peripheral swelling, Erythema, Pain in extremity, |
||||
PIMECROLIMUS, |
||||
| 149 | 25834173 |
US |
68 | 2 |
Eczema, Discomfort, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 150 | 25834178 |
US |
2 | |
Eczema, Rash, Arthralgia, Drug ineffective, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 151 | 25834901 |
US |
66 | 1 |
Eczema, Rebound effect, Intentional dose omission, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 152 | 25835052 |
US |
34 | 2 |
Eczema, |
||||
DUPILUMAB, |
||||
| 153 | 25835388 |
US |
19 | 1 |
Rash macular, Condition aggravated, Inappropriate schedule of product administration, Eczema, Injection site pain, |
||||
DUPILUMAB, DESOXIMETASONE, DESONIDE, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, FLUTICASONE PROPIONATE, LEVOCETIRIZINE DIHYDROCHLORIDE, |
||||
| 154 | 25835434 |
US |
82 | 1 |
Eczema, Drug ineffective, |
||||
DUPILUMAB, |
||||
| 155 | 25835483 |
US |
63 | 2 |
Eczema, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 156 | 25835631 |
US |
2 | |
Eczema, Erythema, Incorrect dose administered, |
||||
DUPILUMAB, |
||||
| 157 | 25835651 |
CA |
2 | |
Psoriatic arthropathy, Monoplegia, Eczema, Vision blurred, Migraine with aura, Vertigo, Nausea, Aphasia, Hypoaesthesia, Tremor, Hot flush, Chills, Dysphagia, Dyspnoea, Tinnitus, Inappropriate schedule of product administration, |
||||
BIMEKIZUMAB, |
||||
| 158 | 25835831 |
US |
41 | 1 |
Eczema, Rash macular, Haemorrhage, Skin burning sensation, Skin discolouration, Pruritus, Erythema, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 159 | 25835997 |
US |
35 | 2 |
Eczema, Rebound effect, Pruritus, |
||||
DUPILUMAB, FISH OIL, ERGOCALCIFEROL, |
||||
| 160 | 25836118 |
US |
2 | 1 |
Eczema, Pruritus, Scratch, Haemorrhage, Erythema, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 161 | 25836123 |
US |
55 | 2 |
Arthralgia, Eczema, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 162 | 25836339 |
US |
59 | 2 |
Eczema, Loss of personal independence in daily activities, Pruritus, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 163 | 25836345 |
US |
63 | 2 |
Eye pruritus, Condition aggravated, Eczema, Pruritus, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 164 | 25836599 |
US |
1 | 1 |
Eczema, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 165 | 25836624 |
US |
45 | 2 |
Eczema, Injection site irritation, |
||||
TRALOKINUMAB-LDRM, |
||||
| 166 | 25836659 |
US |
1 | |
Eczema, Pruritus, Sleep disorder due to a general medical condition, Skin haemorrhage, Skin exfoliation, Dry skin, Skin fissures, |
||||
DUPILUMAB, HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE, HYDROXYZINE HYDROCHLORIDE ORAL, |
||||
| 167 | 25836714 |
US |
3 | 1 |
Hand-foot-and-mouth disease, Eczema, Therapeutic response decreased, |
||||
DUPILUMAB, |
||||
| 168 | 25837200 |
US |
65 | 2 |
Dermatitis atopic, Rash pruritic, Skin fissures, Skin hypertrophy, Pruritus, Eczema, |
||||
DUPILUMAB, |
||||
| 169 | 25837604 |
EU |
2 | |
Eczema, Suicidal ideation, Alopecia, Hyperhidrosis, Hot flush, Emotional disorder, Burning sensation, Rash, Skin atrophy, Fatigue, Insomnia, Night sweats, Skin plaque, Wound, Wound haemorrhage, Fear, Anger, Depressed mood, Skin lesion, |
||||
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE, HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, |
||||
| 170 | 25837919 |
US |
1 | |
Eczema, |
||||
UPADACITINIB, |
||||
| 171 | 25838203 |
US |
44 | 1 |
Eczema, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 172 | 25828675 |
US |
54 | 2 |
Injection site pain, Injection site swelling, Peripheral swelling, Erythema, Skin warm, Idiopathic urticaria, Rebound effect, Eczema, Urticaria, |
||||
DUPILUMAB, |
||||
| 173 | 25828966 |
US |
26 | 1 |
Vision blurred, Eczema, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 174 | 25828972 |
US |
70 | 2 |
Eczema, Rash macular, Skin burning sensation, |
||||
DUPILUMAB, DUPILUMAB, TOBRAMYCIN AND DEXAMETHASONE, FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE NASAL, CYCLOSPORINE, MOMETASONE FUROATE, MOMETASONE, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, MONTELUKAST SODIUM, MONTELUKAST, |
||||
| 175 | 25829002 |
US |
8 | 1 |
Injection site urticaria, Pruritus, Eczema, Rash, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 176 | 25829305 |
US |
66 | 1 |
Eczema, |
||||
DUPILUMAB, |
||||
| 177 | 25829511 |
US |
58 | 1 |
Eczema, Skin swelling, Pain of skin, Rash, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 178 | 25829795 |
CN |
76 | 1 |
Myelosuppression, Eczema, |
||||
DURVALUMAB, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, SODIUM CHLORIDE TABLETS, |
||||
| 179 | 25829879 |
US |
1 | |
Eczema, |
||||
DUPILUMAB, |
||||
| 180 | 25829928 |
US |
5 | 1 |
Eczema, |
||||
DUPILUMAB, |
||||
| 181 | 25829938 |
US |
29 | 2 |
Eczema, Rash, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 182 | 25829949 |
US |
54 | 1 |
Depressed mood, Decreased interest, Feeling of despair, Eczema, Rash, Discomfort, |
||||
DUPILUMAB, FEXOFENADINE HYDROCHLORIDE, CETIRIZINE HCL, CETIRIZINE, HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE, HYDROXYZINE HYDROCHLORIDE ORAL, ALPRAZOLAM, |
||||
| 183 | 25830133 |
CA |
73 | 1 |
Knee arthroplasty, Eczema, |
||||
UPADACITINIB, UPADACITINIB, |
||||
| 184 | 25830160 |
US |
69 | 2 |
Eczema, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 185 | 25830221 |
US |
80 | 1 |
Cerebrovascular accident, Heat exhaustion, Dehydration, General physical health deterioration, Asthenia, Mobility decreased, Eczema, Rebound effect, Pruritus, Contusion, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 186 | 25830602 |
US |
2 | |
Eczema, Rebound effect, Pruritus, Erythema, Product dose omission issue, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 187 | 25830889 |
US |
2 | 2 |
Eczema, |
||||
DUPILUMAB, |
||||
| 188 | 25831226 |
CA |
28 | 2 |
Staphylococcal skin infection, Localised infection, Eczema, Pyoderma gangrenosum, Infected bite, Condition aggravated, |
||||
BUDESONIDE, |
||||
| 189 | 25831272 |
US |
13 | 2 |
Emotional distress, Mood altered, Eczema, Pruritus, Insomnia, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 190 | 25831316 |
US |
33 | 2 |
Vision blurred, Eczema, |
||||
DUPILUMAB, |
||||
| 191 | 25832115 |
US |
1 | |
Eczema, |
||||
DUPILUMAB, |
||||
| 192 | 25833240 |
US |
41 | 2 |
Eczema, Dry skin, Rebound effect, Product dose omission issue, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 193 | 25833244 |
US |
16 | 2 |
Eczema, Therapeutic response shortened, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 194 | 25833623 |
US |
||
Eczema, Drug ineffective, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 195 | 25833705 |
US |
7 | 2 |
Fear of injection, Eczema, Rebound effect, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 196 | 25828086 |
US |
40 | 2 |
Eczema, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 197 | 25828296 |
US |
25 | 2 |
Eczema, Rash, Rebound effect, Therapeutic response decreased, Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 198 | 25826802 |
US |
28 | 2 |
Rash, Rebound effect, Eczema, Product dose omission in error, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 199 | 25827033 |
US |
3 | 2 |
Eczema, |
||||
DUPILUMAB, |
||||
| 200 | 25827139 |
US |
1 | |
Spinal operation, Eczema, |
||||
RISANKIZUMAB-RZAA, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-10-30